RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Per

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a

Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, an

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr.,

Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report)'s stock had its "sell" rating reissued by HC W

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and low

Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of

Squarepoint Ops LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 36.5%

Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy w

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conferenc

U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signe

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses

Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wa

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp

iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while

Alector (NASDAQ: ALEC - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) a

Sarepta Therapeutics Investigation Initiated: Kahn Swick and Foti, LLC Investigates the Officers and

NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, C

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Canada Pension Plan Investment Board purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ: SR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the ana

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to

FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a

– Accepted for review with target action date of February 28, 2027Sarepta Therapeutics, Inc. (NASDAQ

U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps lea

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)

U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, hea

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and

U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49,

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while T

Sarepta stock jumps after siRNA data show protein reduction, while analysts remain split on outlook

In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle